Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15355016 | 1.00 | TSHR (0.39) | TSHRUSP2SPHK1CYP3A4HTT | |
| SCHEMBL11364949 | 1.00 | TSHR (0.39) | TSHRUSP2SPHK1CYP3A4HTT | |
| SCHEMBL12724513 | 0.94 | USP2 (0.43) | TSHRUSP2SPHK1CYP3A4HTT | |
| SCHEMBL12724500 | 0.94 | USP2 (0.43) | TSHRUSP2SPHK1CYP3A4HTT | |
| SCHEMBL12724498 | 0.94 | USP2 (0.43) | TSHRUSP2SPHK1CYP3A4HTT | |
| SCHEMBL12724493 | 0.92 | USP2 (0.46) | TSHRUSP2SPHK1HTTLPAR5 | |
| SCHEMBL12724539 | 0.92 | USP2 (0.46) | TSHRUSP2SPHK1HTTLPAR5 | |
| SCHEMBL12724494 | 0.92 | USP2 (0.46) | TSHRUSP2SPHK1HTTLPAR5 | |
| SCHEMBL12724517 | 0.92 | USP2 (0.46) | TSHRUSP2SPHK1HTTLPAR5 | |
| SCHEMBL1634701 | 0.92 | USP2 (0.46) | TSHRUSP2SPHK1HTTLPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957228-B2 | Macrolide compound having anticancer effect | TOHOKU UNIVERSITY (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20130281714-A1 | MACROLIDE COMPOUND HAVING ANTICANCER EFFECT | TOHOKU UNIVERSITY (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20080125310-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281714-A1 | MACROLIDE COMPOUND HAVING ANTICANCER EFFECT | HDAC6, RPL21, MKI67 | TSHR 4136/4885USP2 3893/4885SPHK1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.